Real-World Registries vs Clinical Trials in Long-Acting Growth Hormone Therapy

In this portion of the discussion, Joshua Yang, MD, contrasts the roles of randomized clinical trials and real-world registries in assessing growth hormone therapies, with a particular focus on long-acting GH analogs. He frames clinical trials as essential for determining whether a therapy can work under controlled conditions, whereas registries are critical for understanding how that therapy performs in routine clinical practice.

Historically, large registries such as KIGS (Pfizer International Growth Database) and NCGS (National Cooperative Growth Study) accumulated decades of data on daily GH therapy, providing robust evidence for long-term efficacy and safety that underpinned clinical confidence in daily GH use.

Yang notes that long-acting GH analogs represent a different class of molecules, even though they are related to daily GH, and therefore warrant their own extensive real-world evaluation. He explains that emerging long-acting GH registries are beginning to generate meaningful longitudinal data, mirroring the process that occurred with daily GH several decades ago.

These registries capture diverse patient populations, extended follow-up periods, and broader clinical scenarios than those represented in registration trials. Over time, these data will help confirm whether the long-term efficacy and safety of long-acting GH analogs align with or differ from those of traditional daily formulations.

Importantly, Yang underscores that registries are particularly valuable for evaluating populations and clinical questions not fully addressed in clinical trials. He highlights, for example, patients with a prior history of malignancy, who are often excluded from randomized trials but appear in real-world datasets. In addition, he points to expanded indications for long-acting GH—such as small for gestational age (SGA), idiopathic short stature, and Noonan syndrome—as areas where registry data can help define expected outcomes across varied clinical settings and geographies.

By capturing real-world patterns of use, efficacy, and safety across diagnoses and regions, registries offer clinicians a more comprehensive evidence base to guide counseling and long-term management decisions for patients treated with long-acting GH analogs.